Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

This study is testing a new personalized immune cell therapy called Innocell — made from the patient's own immune cells — in women with recurrent ovarian, fallopian tube, or peritoneal cancer who have already received platinum-based chemotherapy. **You may be eligible if...** - You are a woman aged 18 or older - You have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer confirmed by biopsy or cytology - You have received at least 1 prior line of platinum-based chemotherapy - Your cancer has returned and you are a candidate for single-agent therapy **You may NOT be eligible if...** - You have carcinosarcoma - You have active or uncontrolled infection - You have received more treatments than the study allows - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.